Extended release methylphenidate for treatment of amphetamine/methamphetamine dependence: a randomised, double-blind, placebo controlled trial
Read time: 1 mins
Published:25th Mar 2020
Aims: To assess the efficacy of methylphenidate as a substitution therapy for amphetamine/methamphetamine dependence in Finland and New Zealand. Design: parallel group, double-blind, randomised placebo controlled trial. Setting: outpatient care. Participants: amphetamine/methamphetamine dependent, aged 16-65. Measurements: The primary outcome measure was presence/absence of amphetamine/methamphetamine in urine samples collected twice weekly. Secondary measures included treatment adherence, alterations in craving scores and self-reported use. Primary analysis was by intention to treat (ITT). Study drug: methylphenidate (as Concerta�) was up-titrated over two weeks to a maximum dose of 54 mg daily and continued for a further 20 weeks. Doses were given under daily supervision at the clinics. Findings: Seventy nine participants were randomised (40 methylphenidate; 39 placebo); 77 received allocated treatment and 27 completed the trial. ITT analysis (N=78) showed no statistically significant difference in the percentage of positive urines between the methylphenidate and placebo arms (OR 0.95, 95% CI 0.83 � 1.08). However, there was a significant difference (p< 0.05) between the active and placebo arms in retention, the placebo arm displaying a significantly lower retention from six weeks that persisted until trial end. Conclusions: The trial failed to replicate earlier findings suggesting that methylphenidate was superior to placebo. The low retention rate confounded the ability to draw firm conclusions about efficacy. The higher retention rate was observed in the methylphenidate arm. Any replication of this work would need to consider alternatives to the rigid clinic attendance criteria, and consider an increased dose.